Man Group PLC Intellia Therapeutics, Inc. Transaction History

Man Group PLC

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$23.82 - $32.8 $3.48 Million - $4.79 Million	-146,119 Reduced 75.28%	47,986 $1.32 Million
Q4 2023 Feb 14, 2024	BUY	$23.16 - $32.34 $4.05 Million - $5.65 Million	174,742 Added 902.45%	194,105 $5.92 Million
Q3 2023 Nov 14, 2023	BUY	$31.62 - $45.78 $612,258 - $886,438	19,363 New	19,363 $612,000
Q4 2022 Feb 14, 2023	BUY	$33.21 - $62.69 $285,971 - $539,823	8,611 Added 39.4%	30,465 $1.06 Million
Q3 2022 Nov 14, 2022	BUY	$53.92 - $71.7 $1.18 Million - $1.57 Million	21,854 New	21,854 $1.22 Million
Q4 2018 Feb 14, 2019	SELL	$11.39 - $27.13 $369,036 - $879,012	-32,400 Closed	0 $0
Q3 2018 Nov 14, 2018	SELL	$25.78 - $32.6 $1.7 Million - $2.15 Million	-65,900 Reduced 67.04%	32,400 $927,000
Q2 2018 Aug 14, 2018	SELL	$20.02 - $30.79 $864,864 - $1.33 Million	-43,200 Reduced 30.53%	98,300 $2.69 Million
Q1 2018 May 15, 2018	BUY	$19.43 - $34.95 $2.75 Million - $4.95 Million	141,500 New	141,500 $2.98 Million

314

91.5M

442K

880K

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $926M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

Get notified when there are updates to the investment portfolio of Man Group PLC, based on Form 13F filings with the SEC.

Stay updated on Man Group PLC with notifications on news.